Muses Labs Showcasing Precision Medicine Technology for Personalized Combination Therapy at Alzheimer’s Association International Conference 2016

Pilot Results from Application of Muses Labs’ Technology-Enabled,
Multi-Modal Protocol for Alzheimer’s Disease are Encouraging and Suggest
Further Study

announced today it will showcase its technology and services at
booth #108 at the Alzheimer’s
Association International Conference (AAIC)
2016 in Toronto, Canada,
July 24-28, 2016. In addition, John Q. Walker, Ph.D., Muses Labs’ chief
technology officer, will present results of pilot work from the
application of the company’s first personalized protocol targeted to
age-related cognitive decline.

Muses Labs’ Protocol is a data-driven, technology-enabled personalized
methodology to correctly identify and simultaneously treat the dozens of
pathology drivers of age-related cognitive decline. It is designed to
help people who are beginning to have symptoms of age-related cognitive
decline, those with a family history of dementia and those with mild
Alzheimer’s disease. Proprietary algorithms within the Protocol
recommend optimal medical interventions personalized for each person
with a goal of improving memory and cognitive function.

Muses Labs has applied its Protocol to more than 125 self-selected
people with cognitive decline in a pilot effort. Each person’s genome,
blood tests, medical history and lifestyle were processed by Muses Labs’
proprietary technology. These individuals then worked with their
physicians to follow their personalized multi-modal protocols. Of those
who completed at least two cycles of protocols over the course of three
or more months, more than 50 percent improved their cognitive function
as measured by industry-standard neuropsych tests. Almost all of those
identified as “early-symptomatic” observed improved memory function and
improvement in key biomarkers.

Dr. Walker will present details of these pilot findings during Session
IV of the AAIC
Technology and Dementia Preconference
. His presentation, “Initial
Development, Application and Results from a Clinical Informatics
Platform that Enables a Multi-Modal Treatment Protocol for Alzheimer’s
Disease,” will be held Saturday, July 23 from 3:10 to 3:30 p.m. Dr.
Walker will also present a poster on clinical therapeutics Monday, July
25 from 9:30 a.m. to 10:30 a.m.

“A multi-modal combination approach has the potential to improve
cognitive function for early-symptomatic individuals,” Dr. Walker said.
“Currently available interventions used in personalized combinations let
individuals with age-related cognitive decline have the potential to
continue their independent and active lifestyles. Our continuing work
with larger populations will further refine our methodology and build a
larger base of quantified patient outcomes. Larger randomized studies of
multi-modal approaches are warranted.”

The Technology and Dementia track convenes researchers using
technological-based research, including mobile technology, home-based
technology and social networking, to apply innovative study design and
potential solutions to Alzheimer’s disease and related dementia
research. The program targets researchers invested in the development
and validation of technological resources for individuals affected by

AAIC is the world’s largest forum for the dementia research community.
International investigators, clinicians and care providers gather
annually to share the latest study results, theories and discoveries
that bring the world closer to breakthroughs in dementia science. As a
part of the association’s research program, AAIC serves as a catalyst
for generating new knowledge about Alzheimer’s and fostering a vital and
collegial research community.

to schedule a time to meet with a Muses Labs team member at AAIC
2016 to learn more about the MEND Protocol and recent study results. For
additional information, please call 984.232.6699 or visit

About Muses Labs

Muses Labs brings together 30 years of scientific research, hundreds of
published clinical studies, and a team of highly respected Alzheimer’s
researchers, doctors and advanced technology. The company applies its
clinical precision medicine platform and technology-enabled protocol to
collect individual patient medical and behavioral data, identify
underlying causes of age-related cognitive decline (such as Alzheimer’s
disease and memory loss) and design personalized treatment plans. A
comprehensive adherence program supports individuals and their
caregivers to improve patient outcomes. This first personalized protocol
is called the MENDTM Protocol (Metabolic Enhancement for
NeuroDegeneration). For more information, visit


Crossroads Public Relations and Marketing
Molly Thompson, Account
Director, 919-821-2822